As a pioneering innovator in the field of targeted radiopharmaceuticals, Dr. Keene Wei, Founder and President of Vitsgen, has been invited as a distinguished speaker at the 3rd Global Nuclear Medicine Development Summit. The summit will be held on March 19, 2026, in Shanghai, focusing on the full-chain innovation of radiopharmaceuticals from laboratory research to clinical translation. The event aims to bring together industry experts, scholars, and corporate representatives to discuss the cutting-edge advancements and industrialization pathways in nuclear medicine R&D, fostering collaboration and exchange within the field.

During the summit, Dr. Keene Wei will deliver a keynote presentation at the main forum titled "Design of Radiopharmaceutical Conjugates: Achieving Target Molecular Radiobiological Dosimetry Characteristics."

Dr. Keene Wei remarked, "Through its successive editions, the Global Nuclear Medicine Development Summit has earned significant recognition within the industry, establishing itself as a key platform for discussing technological progress and sharing practical experiences with peers. I am delighted to be invited to this summit and to share Vitsgen's collaborative design philosophy, which integrates both the 'pharmacokinetic' and 'radiobiological dosimetry' dimensions of targeting molecules. Achieving a delicate synergy between these two aspects is central to the success of next-generation radiopharmaceuticals. We look forward to engaging in in-depth discussions with industry colleagues and jointly advancing the evolution of therapeutic paradigms."

Vitsgen remains committed to building a globally competitive precision nuclear medicine pipeline, anchored by innovative targeting ligands and an intelligent design platform. Dr. Keene Wei's invitation to speak at this prestigious industry event not only reflects the high regard in which he and the Vitsgen team are held by the academic and industrial nuclear medicine communities but also underscores Vitsgen's leading position in the original design of radiopharmaceuticals and its sustained role as a thought leader contributing to the advancement of the field.